Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Kaposi's sarcoma (KS) involving at least 1 of the following areas:~  * Skin~ * Lymph nodes~ * Oral cavity~ * Gastrointestinal tract\*~ * Lungs\* NOTE: \*Must be asymptomatic or minimally symptomatic AND does not require systemic cytotoxic therapy~* Serological documentation of HIV infection, as evidenced by positive enzyme-linked immunosorbent assay (ELISA), Western Blot test, or other federally approved licensed HIV test~* At least 5 measurable, non-irradiated, cutaneous indicator lesions~  * Patients must have 3 lesions at least 5 x 5 mm that are accessible for 4 mm punch biopsy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* At least 3 months~Hematopoietic~* Hemoglobin ≥ 8.0 g/dL~* Absolute neutrophil count ≥ 1,000/mm\^3~* Platelet count ≥ 75,000/mm\^3~Hepatic~* AST and ALT ≤ 2.5 times upper limit of normal~* Bilirubin normal~  * Patients with elevated bilirubin secondary to indinavir or atazanavir allowed provided total bilirubin is \< 3.5 mg/dL AND direct bilirubin is normal~* No acute or known chronic liver disease (e.g., chronic active hepatitis or cirrhosis)~  * Hepatitis C infection with minimal or no fibrosis on liver biopsy allowed~Renal~* Creatinine ≤ 1.5 mg/dL OR~* Creatinine clearance \> 60 mL/min~Cardiovascular~* No New York Heart Association class III or IV cardiac disease~* No congestive heart failure~* No myocardial infarction within the past 6 months~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for 3 months after study participation~* No concurrent active opportunistic infection~* No other severe and/or life-threatening medical disease~* No other malignancy within the past 5 years except clinically insignificant malignancy not requiring active intervention, basal cell skin cancer, or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 4 weeks since prior biologic therapy for KS~* More than 2 weeks since prior granulocyte colony-stimulating factor~* No concurrent biologic agents for KS~Chemotherapy~* More than 4 weeks since prior chemotherapy for KS (6 weeks for nitrosoureas or mitomycin)~* No concurrent chemotherapy for KS, including systemic cytotoxic chemotherapy~Endocrine therapy~* No concurrent systemic corticosteroid therapy except replacement doses~Radiotherapy~* See Disease Characteristics~* More than 4 weeks since prior radiotherapy for KS~* No concurrent radiotherapy for KS~Surgery~* More than 2 weeks since prior major surgery~Other~* No prior imatinib mesylate~* More than 60 days since prior local therapy to any KS indicator lesion unless the lesion has progressed since treatment~* More than 4 weeks since prior investigational therapy for KS~* More than 4 weeks since other prior therapy for KS~* More than 14 days since prior acute treatment for an infection or other serious medical illness~* No concurrent warfarin~* No concurrent grapefruit juice~* No other concurrent therapy for KS~* No other concurrent investigational drugs~* Concurrent antiretroviral therapy required except for patients who have exhausted all available treatment options

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib mesylate (Type: EXPERIMENTAL): Imatinib mesylate (Gleevec) taken 400 mg orally once a day for up to 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete